Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 11 September 2013 | By Alexander Gaffney, RAC,
Funding woes have caused the US Food and Drug Administration (FDA) to cancel a proposed project that would have seen it mining drug adverse event safety signals from literature reports.
FDA regularly puts out requests for proposals and solicitations on the Federal Business Opportunities (FBO) website, and lately has expressed a keen interest in methods of monitoring adverse event data.
In April 2013, for example, it put out a notice indicating it wants a partner to help it build a safety prediction and data mining tool to help it better assess drug adverse event safety signals as early as possible.
That solicitation, which Regulatory Focus wrote about at the time, later morphed into a more thorough (and slightly different) document package, complete with several responses to industry questions by FDA.
The gist of the program, as explained by FDA, is to adopt earlier recommendations by its Science Board to make it easier to mine data and recognize adverse event safety signals automatically.
"An important goal is to allow the development of prospective hypotheses to provide to Office of Surveillance and Epidemiology (OSE) and Office of New Drugs (OND) to inform their evaluation of potential safety signals with the goal of reducing time and effort spent on false positive signals," FDA wrote in the notice.
The intended tool would automatically search the MEDLINE database's massive store of literature reports-a monumental task that might ordinarily take a large team of dedicated and highly educated FDA staff to accomplish.
However, in a new notice on the FBO website, FDA says the entire funding announcement has unfortunately been for naught.
"Due to lack of funding, the requirement has been cancelled," FDA wrote. In a follow-up email to Regulatory Focus, Contract Specialist Trevor Edwards confirmed that, "The entire procurement was cancelled."
The work was originally to start focusing on fluoroquinolone products and lipid-lowering drugs, both products with known safety issues.
It is now unclear whether FDA will resuscitate the program at a later date if its funding situation improves, or whether this is itself an adverse event of budget sequestration.
FBO Cancellation Notice
Tags: Adverse Events
Regulatory Focus newsletters
All the biggest regulatory news and happenings.